ClinicalTrials.gg
Active, not recruitingNCT03121014Updated Oct 13, 2026

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

A Phase 2 interventional study of Fludarabine and Busulfan in Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by University of Illinois at Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Illinois at Chicago · Phase 2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.

Planned enrollment
103rd of 188
38 · median 47
Started
2017
with 9 others
Phase 2
96 of 191
20 open now
Primary completion
2026-11
later than 9 of 48 live
Registered
130th of 191
by date

Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 103rd largest by planned enrollment of the 188 interventional ones that give a count, is one of 10 that started in 2017, is one of 96 in phase 2, reaches primary completion later than 9 of the 48 other live ones, and was the 130th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 34 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies testing fludarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The study is a Phase II clinical trial. Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT).

Read the detailed description

Patients will receive the following conditioning regimen: fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate (see Section 8). Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years
  2. Patients with AML or MDS who meet the following criteria:

    a. AML (including AML in CR2)

    b. Poor-risk AML in first remission, with remission defined as \<5% bone marrow blasts morphologically:

    • AML arising from MDS or a myeloproliferative disorder, or secondary AML
    • Poor risk molecular features including presence of FLT3 internal tandem duplication mutation.
    • Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (> 3 abnormalities), inv(3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7

      c. Primary refractory disease

      d. MDS with at least one of the following poor-risk features:

    • Poor-risk cytogenetics including 3q abnormalities, 7/7q minus or complex cytogenetics (>3 abnormalities)
    • Current or previous INT-2 or high IPSS score
    • Treatment-related MDS
    • MDS diagnosed before age 21 years
    • Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy
    • Life-threatening cytopenias, including those requiring regular PRBC or transfusions e. CML with a history of accelerated or blast phase
  3. Patients must have a related or unrelated peripheral blood stem cell donor as follows:

    1. Sibling donor must be a 6/6 match for HLA-A, -B at intermediate (or higher) resolution and -DRB1 at high resolution using DNA based typing
    2. Unrelated donors must be at least 7/8 match at HLA-A, -B, -C and DRB1 at high resolution using DNA-based typing

Exclusion criteria

Exclusion criteria:

  1. Presence of significant co morbidity as shown by:

    1. \< 50%
    2. \<30ml/min
    3. > 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and and AST > 5 x
    4. and FVC \< 50% of predicted or DLCO \<50% of predicted once corrected for anemia

    f. score \<70 (appendix C)

    g. Hematopoietic cell transplantation comorbidity index >3

    h. Active viral hepatitis or infection

    j. Cirrhosis

  2. Pregnancy
  3. Patients unable to sign
  4. Patient who have previously received radiation to >20% of bone marrow containing areas.

4. DONOR ELIGIBILITY AND SELECTION

4.1. Donor Selection

Donor evaluation and selection is by standard for normal clinical practice. No study procedures are to be performed on donors. All donors must be willing to donate peripheral blood stem cells and meet institutional or NMDP criteria for donation.

The following prioritization will be used when selecting donors:

  1. When possible, an HLA compatible sibling will be used as a donor.
  2. For patients who do not have an HLA compatible sibling, an unrelated donor will be used
  3. 8/8 matched unrelated donors are preferred over single antigen mismatched donors.

If more than one potential volunteer unrelated donor is considered suitable further selection of the most suitable donor is at the discretion of the treating physician. The following serves only as a guide for prioritization:

  1. Age of donor (18-24 > 25-34 > 35-44 > 45+)
  2. Sex and parity of donor (male > female, nulliparous female > parous, multiparous female)
  3. Cytomegalovirus (CMV) status, if recipient is CMV seronegative (CMV- > CMV+)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Patient Treatment

    Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.

    Drug: Fludarabine · Drug: Busulfan · Drug: ATG · Radiation: Total Marrow Irradiation · Procedure: Stem Cell Product Infusion · Drug: Tacrolimus · Drug: Methotrexate

Interventions

  • 40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2

    Also known as: Fludara®

  • targeting a 4800μM/min/ day from day -5 through day -2

    Also known as: Busulfex®

  • DrugAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1

    Also known as: Thymoglobulin®

  • RadiationTotal Marrow Irradiation

    dose of 3Gy on days -3, -2 and -1

  • ProcedureStem Cell Product Infusion

    Day 0 according to BMT unit policy

  • The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.

    Also known as: FK-506, Prograf®

  • 5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11

    Also known as: Trexall®

06

What researchers measure

Primary outcomes

  1. Relapse free survival of approximately 30% in high-risk patients conditioned with the Fludarabine/ Busulfan regimen

    Using a Simon 2 stage optimal design with α of 0.05 and power of 0.8, 15 patients will be enrolled in the first stage. If greater than 5 patients survive to 1 year without relapse the study will continue into stage 2. Recruitment will then continue to a total of 46 patients. In this expanded cohort, if a total of 18 or more patients survive to 1 year without relapse, the treatment will be judged efficacious and worthy of further study.

    Time frame: Up to 1 year

Secondary outcomes

  1. Relapse free survival

    It will be estimated and reported with 90% confidence intervals. The proportion of patients who are alive at 1-year will also be estimated with a 90% exact binomial confidence interval.

    Time frame: Up to 1 year

  2. Overall survival

    It will be estimated and reported with 90% confidence intervals. The proportion of patients who are alive at 1-year will also be estimated with a 90% exact binomial confidence interval.

    Time frame: Up to 1 year

  3. Transplant related mortality rate

    After accrual of 10 patients, analysis will be performed to ensure that the mortality rate does not exceed 30%. By calculation of confidence intervals to ensure the TRM not exceed 30%, accrual would be halted if n= 6 of 10 (lower bound of the exact, one-sided 90% CI is 35.4%).

    Time frame: Up to 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D. Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study. Haematologica. 2026 Jan 1;111(1):177-183. doi: 10.3324/haematol.2025.287457. Epub 2025 Jun 19. PubMed 40534485 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2017 (actual). Primary completion is estimated for Nov 2026, 115 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 115 months is above that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Apr 2026 → Nov 2026 and completion Apr 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2017
First posted
Apr 19, 2017
StartActual
Apr 24, 2017
Primary completionEst.
Nov 2026was Apr 2026
CompletionEst.
Nov 2026was Apr 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Nov 2026
Oct 13, 2026
Study completion
Apr 2026→Nov 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Apr 2026→Nov 2026
    Study completion Apr 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03121014
Responsible party
Damiano Rondelli, MD (Professor, Hematology, University of Illinois at Chicago) — Principal investigator
First posted
Apr 19, 2017
Start date
Apr 24, 2017
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Damiano Rondelli, MD
principal investigator · University of Illinois at Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Busulfan

Start the discussion